Quince buys a rare dis­ease biotech; Heron re­duces head­count

Quince Ther­a­peu­tics will buy the pri­vate biotech Ery­Del SpA in a stock deal, with up to $485 mil­lion on the line in de­vel­op­ment, reg­u­la­to­ry and com­mer­cial biobucks.

Ery­Del stock­hold­ers will own about 16.7% of the com­bined com­pa­ny fol­low­ing the clos­ing, which is ex­pect­ed to oc­cur this quar­ter. Both boards have ap­proved it.

With the deal, Quince said it will have fund­ing to keep the lights on in­to 2026. Its $87.6 mil­lion will bankroll a Phase III clin­i­cal tri­al for Ery­Del’s lead as­set and an NDA sub­mis­sion, pend­ing study re­sults. Ery­Del’s Ery­Dex is be­ing test­ed for a rare pe­di­atric neu­ro­log­i­cal dis­ease known as atax­ia-telang­iec­ta­sia. There are no ap­proved treat­ments for the life-thread­ing con­di­tion, but re­searchers are look­ing in­to cus­tom gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER